Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis


Цитировать

Полный текст

Аннотация

Objectives:Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies, they are highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric antigen receptor (CAR) T cell therapy as a novel immunotherapy to treat malignant T cells faces numerous challenges and is in its early phase. To evaluate this possibility, we aimed to review and meta-analyze the related clinical trials systematically.

Methods:On October 9, 2023, the online databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two‐step title/abstract and full-text screening process, the eligible studies were included.

Results:We observed a pooled overall response rate (ORR) of 100%. Partial response (PR), stringent and/or complete response (sCR/CR), and relapse rate were 6%, 85%, and 18%, respectively. Additionally, the pooled rate of minimal residual disease (MRD) negativity was 85%. The most common grade ≥3 adverse events were related to hematological toxicities, including neutropenia (100%), thrombocytopenia (79%), and anemia (57%). Cytokine release syndrome (CRS) was also a frequent complication with a 100% rate; however, 81% of CRS events were low grades. No grade ≥3 GVHD was reported, and the immune effector cell–associated neurotoxicity syndrome (ICANS grade ≥3) was rare (4%).

Conclusion:CD7 is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (r/r) T-cell malignancies.

Об авторах

Mohsen Dashti

Immunology Research Center, Tabriz University of Medical Sciences

Email: info@benthamscience.net

Mohammad Habibi

Clinical Research Development Center, Qom University of Medical Science and Health Services

Email: info@benthamscience.net

Negar Nejati

Pediatric Cell and Gene Therapy Research Centre, Cell & Tissue Research Institute, Tehran University of Medical Sciences

Email: info@benthamscience.net

Behrouz Robat-Jazi

Department of Immunology, School of Public Health, Tehran University of Medical Sciences

Email: info@benthamscience.net

Mahsa Ahmadpour

Shahid Faghihi Hospital, Shiraz University of Technology

Email: info@benthamscience.net

Negar Dokhani

Cardio-Oncology Research Center, Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences

Email: info@benthamscience.net

Aida Nejad

Stem Cell and Regenerative Medical Center of Excellence, Tehran University of Medical Sciences

Email: info@benthamscience.net

Shaghayegh Karami

School of Medicine, Tehran University of Medical Sciences

Email: info@benthamscience.net

Erfan Alinejad

Department of Medicine, Babol University of Medical Sciences

Email: info@benthamscience.net

Amir Malekijoo

Department of Computer Engineering, Semnan University

Email: info@benthamscience.net

Afsaneh Ghasemzadeh

Immunology Research Center, Tabriz University of Medical Sciences

Email: info@benthamscience.net

Farhad Jadidi-Niaragh

Immunology Research Center, Tabriz University of Medical Sciences

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Teachey, D.T.; Pui, C.H. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol., 2019, 20(3), e142-e154. doi: 10.1016/S1470-2045(19)30031-2 PMID: 30842058
  2. Tan, Y.; Shan, L.; Zhao, L.; Deng, B.; Ling, Z.; Zhang, Y.; Peng, S.; Xu, J.; Duan, J.; Wang, Z.; Yu, X.; Zheng, Q.; Xu, X.; Tian, Z.; Zhang, Y.; Zhang, J.; Chang, A.H.; Feng, X.; Pan, J. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J. Hematol. Oncol., 2023, 16(1), 34. doi: 10.1186/s13045-023-01427-3 PMID: 37020231
  3. Hunger, S.P.; Lu, X.; Devidas, M.; Camitta, B.M.; Gaynon, P.S.; Winick, N.J.; Reaman, G.H.; Carroll, W.L. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J. Clin. Oncol., 2012, 30(14), 1663-1669. doi: 10.1200/JCO.2011.37.8018 PMID: 22412151
  4. den Hoed, MA.; Pluijm, SM.; te Winkel, ML.; de Groot-Kruseman, HA.; Fiocco, M.; Hoogerbrugge, P. Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia. Haematologica, 2015, 100(12), 1564.
  5. Litzow, M.R.; Ferrando, A.A. How I treat T-cell acute lymphoblastic leukemia in adults. Blood, 2015, 126(7), 833-841. doi: 10.1182/blood-2014-10-551895 PMID: 25966987
  6. Bhojwani, D.; Pui, C.H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol., 2013, 14(6), e205-e217. doi: 10.1016/S1470-2045(12)70580-6 PMID: 23639321
  7. Ashry, M.S.E.; Radwan, E.; Abdellateif, M.S.; Arafah, O.; Hassan, N.M. Clinical features, laboratory characteristics, and outcome of ETP and TCRA/D aberrations in pediatric patients with T-acute lymphoblastic leukemia. J. Egypt. Natl. Canc. Inst., 2023, 35(1), 17. doi: 10.1186/s43046-023-00176-1 PMID: 37303010
  8. Polgárová, K.; Otáhal, P.; Šálek, C.; Pytlík, R. Chimeric antigen receptor based cellular therapy for treatment of T-cell malignancies. Front. Oncol., 2022, 12, 876758. doi: 10.3389/fonc.2022.876758 PMID: 35600381
  9. Karsten, H.; Matrisch, L.; Cichutek, S.; Fiedler, W.; Alsdorf, W.; Block, A. Broadening the horizon: potential applications of CAR-T cells beyond current indications. Front. Immunol., 2023, 14, 1285406. doi: 10.3389/fimmu.2023.1285406 PMID: 38090582
  10. Luo, L.; Zhou, X.; Zhou, L.; Liang, Z.; Yang, J.; Tu, S.; Li, Y. Current state of CAR-T therapy for T-cell malignancies. Ther. Adv. Hematol., 2022, 13 doi: 10.1177/20406207221143025 PMID: 36601636
  11. Zhang, X.; Yang, J.; Li, J.; Qiu, L.; Zhang, J.; Lu, Y.; Zhao, Y.; Jin, D.; Li, J.; Lu, P. Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7 ‐targeted chimeric antigen receptor‐T cell therapy. Am. J. Hematol., 2023, 98(12), 1898-1908. doi: 10.1002/ajh.27094 PMID: 37740926
  12. Gomes-Silva, D.; Srinivasan, M.; Sharma, S.; Lee, C.M.; Wagner, D.L.; Davis, T.H.; Rouce, R.H.; Bao, G.; Brenner, M.K.; Mamonkin, M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood, 2017, 130(3), 285-296. doi: 10.1182/blood-2017-01-761320 PMID: 28539325
  13. Cooper, M.L.; Choi, J.; Staser, K.; Ritchey, J.K.; Devenport, J.M.; Eckardt, K.; Rettig, M.P.; Wang, B.; Eissenberg, L.G.; Ghobadi, A.; Gehrs, L.N.; Prior, J.L.; Achilefu, S.; Miller, C.A.; Fronick, C.C.; O’Neal, J.; Gao, F.; Weinstock, D.M.; Gutierrez, A.; Fulton, R.S.; DiPersio, J.F. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia, 2018, 32(9), 1970-1983. doi: 10.1038/s41375-018-0065-5 PMID: 29483708
  14. Pan, J.; Tan, Y.; Wang, G.; Deng, B.; Ling, Z.; Song, W.; Seery, S.; Zhang, Y.; Peng, S.; Xu, J.; Duan, J.; Wang, Z.; Yu, X.; Zheng, Q.; Xu, X.; Yuan, Y.; Yan, F.; Tian, Z.; Tang, K.; Zhang, J.; Chang, A.H.; Feng, X. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial. J. Clin. Oncol., 2021, 39(30), 3340-3351. doi: 10.1200/JCO.21.00389 PMID: 34324392
  15. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg., 2021, 88, 105906. doi: 10.1016/j.ijsu.2021.105906 PMID: 33789826
  16. Slim, K.; Nini, E.; Forestier, D.; Kwiatkowski, F.; Panis, Y.; Chipponi, J. Methodological index for non‐randomized studies ( MINORS ): development and validation of a new instrument. ANZ J. Surg., 2003, 73(9), 712-716. doi: 10.1046/j.1445-2197.2003.02748.x PMID: 12956787
  17. Cochrane handbook for systematic reviews of interventions. 2011. Available from: https://handbook-5-1.cochrane.org/(accessed on 31-7-2024)
  18. Ye, J.; Jia, Y.; Tuhin, I.J.; Tan, J.; Monty, M.A.; Xu, N.; Kang, L.; Li, M.; Lou, X.; Zhou, M.; Fang, X.; Shao, J.; Zhu, H.; Yan, Z.; Yu, L. Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Mol. Ther. Oncolytics, 2022, 24, 719-728. doi: 10.1016/j.omto.2022.02.013 PMID: 35317521
  19. Png, Y.T.; Vinanica, N.; Kamiya, T.; Shimasaki, N.; Coustan-Smith, E.; Campana, D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv., 2017, 1(25), 2348-2360. doi: 10.1182/bloodadvances.2017009928 PMID: 29296885
  20. Lu, P.; Liu, Y.; Yang, J.; Zhang, X.; Yang, X.; Wang, H.; Wang, L.; Wang, Q.; Jin, D.; Li, J.; Huang, X. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood, 2022, 140(4), blood.2021014498. doi: 10.1182/blood.2021014498 PMID: 35500125
  21. Chiesa, R.; Georgiadis, C.; Syed, F.; Zhan, H.; Etuk, A.; Gkazi, S.A. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med., 2023, 389(10), 899-910.
  22. Watanabe, N.; Mo, F.; Zheng, R.; Ma, R.; Bray, V.C.; van Leeuwen, D.G.; Sritabal-Ramirez, J.; Hu, H.; Wang, S.; Mehta, B.; Srinivasan, M.; Scherer, L.D.; Zhang, H.; Thakkar, S.G.; Hill, L.C.; Heslop, H.E.; Cheng, C.; Brenner, M.K.; Mamonkin, M. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol. Ther., 2023, 31(1), 24-34. doi: 10.1016/j.ymthe.2022.09.003 PMID: 36086817
  23. Freiwan, A.; Zoine, J.T.; Crawford, J.C.; Vaidya, A.; Schattgen, S.A.; Myers, J.A.; Patil, S.L.; Khanlari, M.; Inaba, H.; Klco, J.M.; Mullighan, C.G.; Krenciute, G.; Chockley, P.J.; Naik, S.; Langfitt, D.M.; Mamonkin, M.; Obeng, E.A.; Thomas, P.G.; Gottschalk, S.; Velasquez, M.P. Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies. Blood, 2022, 140(25), 2684-2696. doi: 10.1182/blood.2021015020 PMID: 35914226
  24. Wang, X.; Li, S.; Gao, L.; Yuan, Z.; Wu, K.; Liu, L.; Luo, L.; Liu, Y.; Zhang, C.; Liu, J.; Yang, C.; Li, Y.; He, J.; Ye, X.; Li, Z.; Tan, X.; Ge, J.; Cao, W.; Wang, S.; Zhang, X. Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). J. Clin. Oncol., 2020, 38(15_suppl), 3013. doi: 10.1200/JCO.2020.38.15_suppl.3013
  25. Ghobadi, A.; Aldoss, I.; Maude, S.L.; Bhojwani, D.; Wayne, A.S.; Bajel, A.; Faramand, R.; Mattison, R.J.; Dholaria, B.; Rettig, M.P.; Jacobs, K.; Bakkacha, O.; Muth, J.; Pannunzio, A.; Ramsey, B.; McNulty, E.; Cooper, M.L.; Davidson-Moncada, J.; DiPersio, J.F. Phase 1/2 dose-escalation/dose-expansion study of anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). Blood, 2023, 142(Suppl. 1), 770. doi: 10.1182/blood-2023-178723
  26. Zhang, X.; Zhou, Y.; Yang, J.; Li, J.; Qiu, L.; Ge, W.; Pei, B.; Chen, J.; Han, L.; Ren, J.; Lu, P. A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood, 2022, 140(Suppl. 1), 4566-4567. doi: 10.1182/blood-2022-165733
  27. Zhao, L.; Pan, J.; Tang, K.; Tan, Y.; Deng, B.; Ling, Z.; Song, W.; Chang, A.H.; Feng, X. Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma. J. Clin. Oncol., 2022, 40(16_suppl), 7035. doi: 10.1200/JCO.2022.40.16_suppl.7035
  28. Hu, K.; Yang, F.; Shi, H.; Liu, R.; Zheng, P.; Feng, S.; Guo, Y. P1236: Efficacy and toxicity for CD7 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory T-cell lymphoma. HemaSphere, 2022, 6, 1121-1122. doi: 10.1097/01.HS9.0000847808.59949.f6
  29. Zhang, X.; Yang, J.; Li, J.; Shi, Y.; Su, Y.; Liu, Y.; Ba, M.; Wu, Y.; Li, W.; Li, J.; Lu, P. First-in-human clinical study of a novel CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory/relapsed mixed phenotype acute leukemia (MPAL). Blood, 2021, 138(Suppl. 1), 1741. doi: 10.1182/blood-2021-146425
  30. Cheng, J.; Wang, J.; Mao, X.; Mu, W.; Sun, S.; Zhou, X.; Huang, L. Phase 1 dose escalation study of the anti-CD7 CAR-T therapy in relapsed/refractory T-cell acute leukemia and lymphoblastic lymphoma. Blood, 2023, 142(Suppl. 1), 6863. doi: 10.1182/blood-2023-184370
  31. Zhang, M.; Chen, D.; Fu, X.; Meng, H.; Nan, F.; Sun, Z.; Yu, H.; Zhang, L.; Li, L.; Li, X.; Wang, X.; Wang, M.; You, F.; Li, Z.; Chang, Y.; Zhou, Z.; Yan, J.; Li, J.; Wu, X.; Wang, Y.; Wang, Y.; Xiang, S.; Chen, Y.; Pan, G.; Xu, H.; Zhang, B.; Yang, L. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin. Cancer Res., 2022, 28(13), 2830-2843. doi: 10.1158/1078-0432.CCR-21-4097 PMID: 35435984
  32. Zhang, Y.; Li, C.; Du, M.; Jiang, H.; Luo, W.; Tang, L.; Kang, Y.; Xu, J.; Wu, Z.; Wang, X.; Huang, Z.; Zhang, Y.; Wu, D.; Chang, A.H.; Hu, Y.; Mei, H. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J., 2023, 13(1), 61. doi: 10.1038/s41408-023-00822-w PMID: 37095094
  33. Becerril-Rico, J.; Delgado-Montes, Y.A.; Ortiz-Sánchez, E. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review. Leuk. Lymphoma, 2023, 64(11), 1822-1831. doi: 10.1080/10428194.2023.2243357 PMID: 37548560
  34. Kim, M.Y.; Cooper, M.L.; Jacobs, M.T.; Ritchey, J.K.; Hollaway, J.; Fehniger, T.A.; DiPersio, J.F. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI Insight, 2021, 6(16), e149819. doi: 10.1172/jci.insight.149819 PMID: 34423790
  35. Bonilla, F.; Kokron, C.M.; Swinton, P.; Geha, R.S. Targeted gene disruption of murine CD7. Int. Immunol., 1997, 9(12), 1875-1883. doi: 10.1093/intimm/9.12.1875 PMID: 9466315
  36. Lee, D.M.; Staats, H.F.; Sundy, J.S.; Patel, D.D.; Sempowski, G.D.; Scearce, R.M.; Jones, D.M.; Haynes, B.F. Immunologic characterization of CD7-deficient mice. J. Immunol., 1998, 160(12), 5749-5756. doi: 10.4049/jimmunol.160.12.5749 PMID: 9637484
  37. Wudhikarn, K.; Perales, M.A. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant., 2022, 57(10), 1477-1488. doi: 10.1038/s41409-022-01756-w PMID: 35840746
  38. Aamir, S.; Anwar, M.Y.; Khalid, F.; Khan, S.I.; Ali, M.A.; Khattak, Z.E. Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes. Clin. Lymphoma Myeloma Leuk., 2021, 21(4), e334-e347. doi: 10.1016/j.clml.2020.12.010 PMID: 33573914

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2025